Clinical Trial

A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 02(BTC&HCC)]

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
An open-label, multicenter, phase II clinical study to evaluate the efficacy and safety of LBL-024 in combination with other drugs for the treatment of patients with advanced solid tumour.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2025-08-01; most recent amendment 2026-05-22.
Status change: Not Yet Recruiting → Recruiting 2025-11-25
Trial Details
NCT Number NCT07111546
Lead Sponsor Nanjing Leads Biolabs Co.,Ltd
Collaborators: Shanghai Zhongshan Hospital
Conditions Advanced Solid Tumour
Enrollment 140 participants
Start Date 2025-10-20
Primary Completion 2027-12-26 (estimated)
Study Completion 2027-12-26 (estimated)
Updated on ClinicalTrials.gov 2026-05-26